SCHEDULE 13G/A: Schonfeld Strategic Advisors Amends Stake in Applied Therapeutics, Reports 3.30% Passive Ownership
Beneficial Ownership Disclosure
Schonfeld Strategic Advisors LLC has filed an amended Schedule 13G, disclosing a 3.30% beneficial ownership stake in Applied Therapeutics, Inc. as of March 31, 2025.
Summary
- Schonfeld Strategic Advisors LLC, an investment adviser, filed an Amendment No. 1 to Schedule 13G regarding its holdings in Applied Therapeutics, Inc.
- As of March 31, 2025, Schonfeld beneficially owned 4,676,097 shares of Applied Therapeutics, Inc. common stock.
- This ownership represents 3.30% of the issuer's common stock outstanding.
- The percentage is calculated based on 141,575,526 shares of common stock outstanding as of April 11, 2025, as reported in Applied Therapeutics' definitive proxy statement filed on April 28, 2025.
- Schonfeld holds sole voting power and sole dispositive power over all 4,676,097 shares.
- The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing disclosing an institutional investor's passive ownership stake. It provides factual information without expressing explicit sentiment regarding the issuer's performance or future.
Positives
- A significant institutional investor, Schonfeld Strategic Advisors LLC, maintains a disclosed stake in Applied Therapeutics, Inc., indicating continued investment interest.
Negatives
- The current beneficial ownership of 3.30% is below the 5% threshold typically associated with significant passive stakes, potentially indicating a reduction from a prior higher holding, though the previous percentage is not disclosed in this amendment.
Risks
- Schonfeld Strategic Advisors LLC explicitly states that the filing does not constitute an admission that they are the beneficial owner of the securities for all purposes of Section 13(d) or 13(g) of the Securities Exchange Act of 1934.
Future Outlook
NA
Management Comments
- Schonfeld Strategic Advisors LLC certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of or with the effect of changing or influencing the control of Applied Therapeutics, Inc.
Industry Context
NA
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires filing of this statement. |
| 04/11/2025 | Date as of which 141,575,526 shares of common stock were outstanding, used for percentage calculation. |
| 04/28/2025 | Date Applied Therapeutics, Inc. filed its definitive proxy statement with the SEC, containing the outstanding share count. |
| 05/15/2025 | Date of signing and filing of this Schedule 13G Amendment No. 1. |
Keywords
Applied Therapeutics Inc., Schonfeld Strategic Advisors LLC, Schedule 13G, SEC filing, beneficial ownership, institutional investor, common stock, investment adviser, passive investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.